Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Financing Activities (2016 - 2025)

Neurocrine Biosciences' Cash from Financing Activities history spans 16 years, with the latest figure at $37.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 112.86% year-over-year to $37.3 million; the TTM value through Dec 2025 reached -$38.3 million, up 92.13%, while the annual FY2025 figure was -$38.3 million, 92.13% up from the prior year.
  • Cash from Financing Activities reached $37.3 million in Q4 2025 per NBIX's latest filing, down from $45.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $69.9 million in Q1 2024 to a low of -$293.0 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is -$33.3 million, with a median of $7.8 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 1266.67% in 2022, then plummeted 10203.45% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.8 million in 2021, then soared by 1266.67% to $24.6 million in 2022, then surged by 43.9% to $35.4 million in 2023, then tumbled by 919.21% to -$290.0 million in 2024, then skyrocketed by 112.86% to $37.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Cash from Financing Activities are $37.3 million (Q4 2025), $45.6 million (Q3 2025), and -$3.3 million (Q2 2025).